Modeling Clinical Outcomes in Gambling Addiction

Gambling disorder (GD) is recognized as an addictive disorder. Financial consequences of GD are often dramatic, inducing professional, familial, legal and medical repercussions and particularly mental health consequences.

MOGADOR is a longitudinal, multicentric, prospective, prognostic study, which aims to identify factors predicting the evolution of french patients with GD in care centers particularly involved in the management of GD. The main goal will focus on evolution of DSM-5 (Diagnostic and Statistical Manual of Mental Disorder 5th edition) GD criteria during the first year of follow-up. The prognostic factors will be collected at base-line and they will be considered to influence the long-term prognosis of patients.

For patients suffering of GD, our main hypothesis is that initial factors like individual socio-demographic characteristics, clinical psychiatric profiles, addiction comorbidities, and behaviour are associated with the clinical prognosis (total remission of DSM-5 criteria of GD at 12 months).

MOGADOR will be the first study, aiming to model prognostic aspects of GB in populations specially monitored for this disorder.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Gambling Disorder Behavior Disruptive, Impulse Control, and Conduct Disorders Gambling Mental Disorders Risk-Taking

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hôpital Jen Minjoz, CHU de Besançon, Besançon, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patient, male or female, over 18 years old, consulting in one of the participating centers.
DSM-5 criteria for gambling disorder at inclusion: at least 4 criteria present in the 12 months preceding the study.
First treatment for gambling disorder or no treatment in the last 6 months (initiation or re-initiation of care).

Exclusion criteria

Unable to be reached by phone.
Unable to use the internet.
Patient under antiparkinsonian treatment of the dopaminergic family.
Being treated with a drug that may trigger/increase symptoms of gambling disorder (e.g. dopamine agonist).
Subject under guardianship.

Treatment and study plan

Primary outcomes

Partial remission of gambling disorder at 12 months (strictly less than 4 DSM-5 criteria)

Time frame: DSM-5 criteria assessment will be conducted at 9 and 12 months after inclusion.

Assessment of DSM-5 criteria will be performed by the clinician, and by a previously trained CRA if clinical follow-up is discontinued.
modeling prognostic factors

Time frame: at inclusion visit.
The prognostic factors, studied will be: number of initial DSM-5 criteria, gender, age, marital status, housing, employment status, socioeconomic level, time spent gambling, impulsivity, type of gambling, location of gambling, and also the factor with the strongest association in univariate analysis among the following factors:
- Depression (PHQ scale),
- Anxiety (GAD scale),
- Quality of life (SF-36 scale).

Study contacts

Contact information is provided by the study sponsor or research team.

Pauline DROUIN

CONTACT

[email protected]

Véronique FONTEILLE, MD, PhD

CONTACT

[email protected]

04 72 11 80 64

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Acronym: MOGADOR

Important dates

Study start: 2025
Primary completion: 2029
Study completion: 2030
First posted: May 20, 2025
Registry last updated: May 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting